|
Comments
Did you read today's front page stories & breaking news?
SYS-CON.TV
|
From the Wires
Active Biotech AB Interim report January - September 2012
By: Marketwire .
Nov. 9, 2012 02:41 AM
LUND, SWEDEN -- (Marketwire) -- 11/09/12 --
· TASQ - biomarker data presented at the ESMO conference - Ipsen to initiate two new clinical Phase II studies: maintenance therapy for prostate cancer and a study of other types of cancer · ANYARA - Phase III study results to be presented Q1 2013 · 57-57 - clinical trial of systemic sclerosis/scleroderma is in progress · ISI - project proceeding as planned · Net sales: SEK 136.4 M (231.3) · Operating loss: SEK 168.7 M (loss 6.2) · Loss after tax: SEK 175.1 M (loss: 1.3) · Loss per share for the period: SEK 2.54 (loss: 0.02) This report is also available at www.activebiotech.com Active Biotech AB Interim report January - September 2012: http://hugin.info/1002/R/1656396/535516.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Active Biotech via Thomson Reuters ONE [HUG#1656396] For further information, please contact: SOA World Latest Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
|
SYS-CON Featured Whitepapers
Most Read This Week |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||